Nana Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nana Zhang has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Ran Ju
National Local Joint Engineering Research Center for Precision Surgery and Regenerative Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
5 shared publicationsShenao Qu
5 shared publicationsShiran Tao
National Local Joint Engineering Research Center for Precision Surgery and Regenerative Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
5 shared publicationsYi Lyu
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
5 shared publicationsHaoyang Zhu
Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
4 shared publicationsJing Leng
Xi’an Jiaotong University Health Science Center, Xi’an, China
4 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Springer Nature in BioMedical Engineering OnLine
Safety and feasibility of transvascular pulsedfield ablation for orthotopic liver tumor in a rabbit model
- 11 November 2026
- Published by Springer Nature in BioMedical Engineering OnLine
Open AccessSafety and feasibility of transvascular pulsedfield ablation for orthotopic liver tumor in a rabbit model
- Open Access
- 23 July 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Technical safety and efficacy of PFA catheter electrode for airway ablation in a rat model of COPD
- 23 July 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Open AccessTechnical safety and efficacy of PFA catheter electrode for airway ablation in a rat model of COPD
- Open Access
- 24 December 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-15
Association between the female hormone intake and cardiovascular disease in the women: a study based on NHANES 1999–2020
Although many studies have reported the relationship between female hormone intake and cardiovascular disease (CVD) development, their association has not been fully elucidated and defined, based on data from the Third National Health and Nutrition Examination Survey intending to assess the health and nutritional status of non-institutionalized children and adults in the United States. This study examined the relationship between female hormone intake and coronary artery disease (CVD) development in 38,745 women, averaging 38.10 ± 12.59 years in age. We explored the association between hormone intake and CVD incidence, considering various social determinants of health (SDOH) with statistical methods like Chi-square tests, logistic regression, and stratified Chi-square analysis. Our findings reveal a complex relationship between female hormone intake and CVD development. Hormones appear to reduce CVD risk in women over 60 years old. However, hormone intake correlates with increased CVD risk in highly educated women. Socioeconomic status also influences this relationship; while hormones pose a risk factor for heart failure and stroke in impoverished or wealthy women, they serve as a protective factor against CVD for middle-income women. Additionally, hormonal intake seems beneficial for women who experienced menarche between 13 and 15 years old, menopause between 30 and 49, and had 7–9 pregnancies, especially when coupled with a diet low in sugar, fat, cholesterol, and adequate folic acid intake. These results indicate that while hormones can prevent CVD under specific conditions, their impact can be detrimental in different SDOH contexts. In conclusion, while appropriate hormone intake can prevent CVD, its effects vary across different demographic and health backgrounds. This underscores the necessity for meticulous screening of SDOH factors in clinical settings to maximize the protective benefits of hormones against CVD.
- 24 December 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-15
Open AccessAssociation between the female hormone intake and cardiovascular disease in the women: a study based on NHANES 1999–2020
Although many studies have reported the relationship between female hormone intake and cardiovascular disease (CVD) development, their association has not been fully elucidated and defined, based on data from the Third National Health and Nutrition Examination Survey intending to assess the health and nutritional status of non-institutionalized children and adults in the United States. This study examined the relationship between female hormone intake and coronary artery disease (CVD) development in 38,745 women, averaging 38.10 ± 12.59 years in age. We explored the association between hormone intake and CVD incidence, considering various social determinants of health (SDOH) with statistical methods like Chi-square tests, logistic regression, and stratified Chi-square analysis. Our findings reveal a complex relationship between female hormone intake and CVD development. Hormones appear to reduce CVD risk in women over 60 years old. However, hormone intake correlates with increased CVD risk in highly educated women. Socioeconomic status also influences this relationship; while hormones pose a risk factor for heart failure and stroke in impoverished or wealthy women, they serve as a protective factor against CVD for middle-income women. Additionally, hormonal intake seems beneficial for women who experienced menarche between 13 and 15 years old, menopause between 30 and 49, and had 7–9 pregnancies, especially when coupled with a diet low in sugar, fat, cholesterol, and adequate folic acid intake. These results indicate that while hormones can prevent CVD under specific conditions, their impact can be detrimental in different SDOH contexts. In conclusion, while appropriate hormone intake can prevent CVD, its effects vary across different demographic and health backgrounds. This underscores the necessity for meticulous screening of SDOH factors in clinical settings to maximize the protective benefits of hormones against CVD.
- 14 May 2024
- Published by Elsevier in Life Sciences
- Vol. 349, 122718
Challenges in clinical practice, biological mechanism and prospects of physical ablation therapy for COPD
- 14 May 2024
- Published by Elsevier in Life Sciences
- Vol. 349, 122718
Challenges in clinical practice, biological mechanism and prospects of physical ablation therapy for COPD
- 7 May 2024
- Published by Elsevier in Bioelectrochemistry
- Vol. 158, 108726
Advantages of pulsed electric field ablation for COPD: Excellent killing effect on goblet cells
- 7 May 2024
- Published by Elsevier in Bioelectrochemistry
- Vol. 158, 108726
Advantages of pulsed electric field ablation for COPD: Excellent killing effect on goblet cells
- 1 January 2024
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 52 (01) , 137-160
The Effectiveness of Traditional Chinese Medicine in Treating Malignancies via Regulatory Cell Death Pathways and the Tumor Immune Microenvironment: A Review of Recent Advances
Traditional Chinese Medicine (TCM) has achieved high clinical efficacy in treating malignancies in recent years and is thus gradually becoming an important therapy for patients with advanced tumor for its benefits in reducing side effects and improving patients’ immune status. However, it has not been internationally recognized for cancer treatment because TCM’s anti-tumor mechanism is not fully elucidated, limiting its clinical application and international promotion. This review traced the mechanism of the TCM-mediated tumor cell death pathway and its effect on remodeling the tumor immune microenvironment, its direct impact on the microenvironment, its anti-tumor effect in combination with immunotherapy, and the current status of clinical application of TCM on tumor treatment. TCM can induce tumor cell death in many regulatory cell death (RCD) pathways, including apoptosis, autophagy, pyroptosis, necroptosis, and ferroptosis. In addition, TCM-induced cell death could increase the immune cells’ infiltration with an anti-tumor effect in the tumor tissue and elevate the proportion of these cells in the spleen or peripheral blood, enhancing the anti-tumor capacity of the tumor-bearing host. Moreover, TCM can directly affect immune function by increasing the population or activating the sub-type immune cells with an anti-tumor role. It was concluded that TCM could induce a pan-tumor death modality, remodeling the local TIME differently. It can also improve the systemic immune status of tumor-bearing hosts. This review aims to establish a theoretical basis for the clinical application of TCM in tumor treatment and to provide a reference for TCM’s potential in combination with immunotherapy in cancer treatment.
- 1 January 2024
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 52 (01) , 137-160
The Effectiveness of Traditional Chinese Medicine in Treating Malignancies via Regulatory Cell Death Pathways and the Tumor Immune Microenvironment: A Review of Recent Advances
Traditional Chinese Medicine (TCM) has achieved high clinical efficacy in treating malignancies in recent years and is thus gradually becoming an important therapy for patients with advanced tumor for its benefits in reducing side effects and improving patients’ immune status. However, it has not been internationally recognized for cancer treatment because TCM’s anti-tumor mechanism is not fully elucidated, limiting its clinical application and international promotion. This review traced the mechanism of the TCM-mediated tumor cell death pathway and its effect on remodeling the tumor immune microenvironment, its direct impact on the microenvironment, its anti-tumor effect in combination with immunotherapy, and the current status of clinical application of TCM on tumor treatment. TCM can induce tumor cell death in many regulatory cell death (RCD) pathways, including apoptosis, autophagy, pyroptosis, necroptosis, and ferroptosis. In addition, TCM-induced cell death could increase the immune cells’ infiltration with an anti-tumor effect in the tumor tissue and elevate the proportion of these cells in the spleen or peripheral blood, enhancing the anti-tumor capacity of the tumor-bearing host. Moreover, TCM can directly affect immune function by increasing the population or activating the sub-type immune cells with an anti-tumor role. It was concluded that TCM could induce a pan-tumor death modality, remodeling the local TIME differently. It can also improve the systemic immune status of tumor-bearing hosts. This review aims to establish a theoretical basis for the clinical application of TCM in tumor treatment and to provide a reference for TCM’s potential in combination with immunotherapy in cancer treatment.
- Open Access
- 24 October 2023
- Published by Springer Nature in Research Square
Association between the female hormone intake and coronary artery disease in the women: A study based on NHANES 1999-2020
Although many studies have reported the relationship between female hormone intake and the coronary artery disease(CAD) development their association has not been elucidated and defined. Based on data from the Third National Health and Nutrition Examination Survey, this study assessed the relation between female hormone intake and the CAD development in 38745 eligible female participants. Many sociocultural determinants of health (SDOH) factors are significantly related to CAD occurrence and female hormone intake. Stratified analysis of SDOH factors showed that female hormone intake reduces the risk of CAD in women aged ≥ 60 years old. For women who received higher levels of education, female hormone intake is a risk factor for CAD. For women in poverty or wealth, female hormone intake is a risk factor for congestive heart failure and stroke, but it is a protective factor for the four clinical features of CAD for women in middle-income levels. Moreover, for women with menarche at 13–15 years old, menopause at 30–49 years old, and pregnancies 7–9 times, as well as with a low-sugar, low-fat, low-cholesterol diet and proper folic acid intake, female hormone intake have a protective effect on the development of CAD. We conclude that the appropriate female hormone intake plays a protective role in the occurrence of CAD, but it also exerts an adverse effect on CAD under a different SDOH background. It suggested that the patients must be rigorously screened for SODH background in clinical applications of female hormones to exert a protective effect on CAD.
- 24 October 2023
- Published by Springer Nature in Research Square
Open AccessAssociation between the female hormone intake and coronary artery disease in the women: A study based on NHANES 1999-2020
Although many studies have reported the relationship between female hormone intake and the coronary artery disease(CAD) development their association has not been elucidated and defined. Based on data from the Third National Health and Nutrition Examination Survey, this study assessed the relation between female hormone intake and the CAD development in 38745 eligible female participants. Many sociocultural determinants of health (SDOH) factors are significantly related to CAD occurrence and female hormone intake. Stratified analysis of SDOH factors showed that female hormone intake reduces the risk of CAD in women aged ≥ 60 years old. For women who received higher levels of education, female hormone intake is a risk factor for CAD. For women in poverty or wealth, female hormone intake is a risk factor for congestive heart failure and stroke, but it is a protective factor for the four clinical features of CAD for women in middle-income levels. Moreover, for women with menarche at 13–15 years old, menopause at 30–49 years old, and pregnancies 7–9 times, as well as with a low-sugar, low-fat, low-cholesterol diet and proper folic acid intake, female hormone intake have a protective effect on the development of CAD. We conclude that the appropriate female hormone intake plays a protective role in the occurrence of CAD, but it also exerts an adverse effect on CAD under a different SDOH background. It suggested that the patients must be rigorously screened for SODH background in clinical applications of female hormones to exert a protective effect on CAD.
- 23 September 2023
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 101 (11) , 1355-1363
Immunogenic necroptosis in liver diseases: mechanisms and therapeutic potential
Necroptosis has received increasing attention and is extensively studied as a recently discovered mode of cell death distinct from necrosis and apoptosis. It is a programmed cell death with a necrotic morphology that occurs in various biological processes, including inflammation, immune response, embryonic development, and metabolic abnormalities. Necroptosis is indispensable in maintaining tissue homeostasis in vivo and closely correlates with the occurrence and development of various diseases. First, we outlined the etiology of necroptosis and how it affects the onset and development of prevalent liver diseases in this review. Additionally, we reviewed the therapeutic strategy by targeting the necroptosis pathway in related liver diseases. We conclude that the necroptosis signaling pathway is critical in the physiological control of liver diseases’ onset, progression, and prognosis. It will likely be used as a therapeutic target in the future. Further research is required to determine the mechanisms governing the necroptosis signaling pathway and the effector molecules.
- 23 September 2023
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 101 (11) , 1355-1363
Immunogenic necroptosis in liver diseases: mechanisms and therapeutic potential
Necroptosis has received increasing attention and is extensively studied as a recently discovered mode of cell death distinct from necrosis and apoptosis. It is a programmed cell death with a necrotic morphology that occurs in various biological processes, including inflammation, immune response, embryonic development, and metabolic abnormalities. Necroptosis is indispensable in maintaining tissue homeostasis in vivo and closely correlates with the occurrence and development of various diseases. First, we outlined the etiology of necroptosis and how it affects the onset and development of prevalent liver diseases in this review. Additionally, we reviewed the therapeutic strategy by targeting the necroptosis pathway in related liver diseases. We conclude that the necroptosis signaling pathway is critical in the physiological control of liver diseases’ onset, progression, and prognosis. It will likely be used as a therapeutic target in the future. Further research is required to determine the mechanisms governing the necroptosis signaling pathway and the effector molecules.
- 5 December 2022
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 181, 103893
The prognostic impact of tumor-infiltrating B lymphocytes in patients with solid malignancies: A systematic review and meta-analysis
- 5 December 2022
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 181, 103893
The prognostic impact of tumor-infiltrating B lymphocytes in patients with solid malignancies: A systematic review and meta-analysis